Related references
Note: Only part of the references are listed.High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis
Andrea Calcagno et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1-Infected Patients: Final 5-Year Results From STARTMRK
Juergen K. Rockstroh et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naive HIV-Infected Patients
Matthew L. Rizk et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects
Dario Cattaneo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-Infected Patients
Dario Cattaneo et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium
Susan E. Dorman et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting
Marco Siccardi et al.
THERAPEUTIC DRUG MONITORING (2012)
Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions
Min-Koo Choi et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2011)
Lack of a Clinically Meaningful Pharmacokinetic Effect of Rifabutin on Raltegravir: In Vitro/In Vivo Correlation
Diana M. Brainard et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics
Diana M. Brainard et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor
Diana M. Brainard et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
New Regimens to Prevent Tuberculosis in Adults with HIV Infection
Neil A. Martinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Timothy R. Sterling et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir With and Without Maraviroc Coadministration
Silvia Baroncelli et al.
ANNALS OF PHARMACOTHERAPY (2010)
Pharmacokinetics and Pharmacogenomics of Once-Daily Raltegravir and Atazanavir in Healthy Volunteers
Michael Neely et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Identification of genetic polymorphisms of human OAT1 and OAT2 genes and their relationship to hOAT2 expression in human liver
Ho Jung Shin et al.
CLINICA CHIMICA ACTA (2010)
Effects of Isatin-lsoniazid Derivatives on Drug Metabolizing and Chemoprotective Enzymes in Mice
Wael M. El-Sayed et al.
DRUG DEVELOPMENT RESEARCH (2010)
Safety and Efficacy of Raltegravir in HIV-Infected Transplant Patients Cotreated with Immunosuppressive Drugs
L. Tricot et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir
Larissa A. Wenning et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Update on rifampin and rifabutin drug interactions
Anne M. Baciewicz et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2008)
Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations
Kelly Dooley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS
S. A. Merschman et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers
Y. Y. Lau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism
Justine L. Lam et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis
Ian M. Rosenthal et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts
M Schechter et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide
TB Bidstrup et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Pharmacokinetic interactions with rifampicin - Clinical relevance
M Niemi et al.
CLINICAL PHARMACOKINETICS (2003)
Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex
P Bemer-Melchior et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
Share Paper
